During the last session, Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares were 3.37 million, with the beta value of the company hitting 1.96. At the end of the trading day, the stock’s price was $4.46, reflecting an intraday loss of -1.98% or -$0.09. The 52-week high for the FATE share is $8.83, that puts it down -97.98 from that peak though still a striking 63.45% gain since the share price plummeted to a 52-week low of $1.63. The company’s market capitalization is $507.68M, and the average trade volume was 2.43 million shares over the past three months.
Fate Therapeutics Inc (FATE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.56. FATE has a Sell rating from 1 analyst(s) out of 8 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Fate Therapeutics Inc (FATE) registered a -1.98% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.98% in intraday trading to $4.46, hitting a weekly high. The stock’s 5-day price performance is 42.95%, and it has moved by 23.55% in 30 days. Based on these gigs, the overall price performance for the year is -4.29%.
The extremes of the forecast give a target low and a target high price of $4 and $145 respectively. As a result, FATE is trading at a discount of -3151.12% off the target high and 10.31% off the low.
Fate Therapeutics Inc (FATE) estimates and forecasts
Statistics show that Fate Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Fate Therapeutics Inc (FATE) shares have gone down -1.11% during the last six months, with a year-to-date growth rate less than the industry average at -15.85% against 15.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.65%. While earnings are projected to return -12.94% in 2024.
FATE Dividends
Fate Therapeutics Inc is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.